Cost effectiveness of paliperidone palmitate versus risperidone long-Acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 844-861

  Mehnert, Angelika ^a   Nicholl, Deborah ^b   Pudas, Hanna ^c   Martin, Monique ^d   McGuire, Alistair ^e  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Janssen Cilag Oy   (Finland)

^d OPTUM   (United States)

^e LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Adherence; Atypical antipsychotic; Cost effectiveness analysis; Long Acting therapy; Relapse; Schizophrenia

Indexed keywords

CLOZAPINE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ARTICLE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; MORTALITY; PATIENT COMPLIANCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SWEDEN; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DRUG SUBSTITUTION; FEMALE; HEALTH RESOURCES; HUMANS; INJECTIONS; ISOXAZOLES; MALE; MARKOV CHAINS; MODELS, ECONOMIC; PALMITATES; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SWEDEN;

EID: 84865240982     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.681531     Document Type: Article

References (58)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Revised 4th ed). Washington: APA, 2000
2. National Institute of Clinical Excellence. CG82 Schizophrenia: Full guideline (2010). http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf. Accessed March 8 2012
3. McGrath J, Saha S, Chant D, et al. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
4. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
5. Lindstrom E, Eberhard J, Neovius M, et al. Costs of schizophrenia during 5 years. Acta Psychiatr Scand 2007;116:33-40
6. Chang SM, Cho SJ, Jeon HJ, et al. Economic burden of schizophrenia in South Korea. J Korean Med Sci 2008;23:167-75
7. Ascher-Svanum H, Baojin Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
8. Fitzgerald P, de Castella A, Arya DS, et al. The cost of relapse in schizophrenia and schizoaffective disorder. Australas Psychiatry 2009;17:265-72
9. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
10. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
11. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
12. Morken G, Widen JH, Grawe RW. Non-Adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32
13. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-Acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
14. Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-Acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26:501-9
15. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients. J Clin Psychiatry 1996;57:337-45
16. Haycox A. Pharmacoeconomics of long-Acting risperidone: Results and validity of cost-effectiveness models. Pharmacoeconomics 2005;23:3-16
17. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-Acting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35:2367-77
18. Kane JM, Detke HC, Naber D, et al. Olanzapine long-Acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
19. Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. The Cochrane Collaboration, John Wiley & Sons, Ltd, Issue 5, 2010
20. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. The Cochrane Collaboration, John Wiley & Sons, Ltd, Issue 5, 2010
21. Review and evaluation of clinical data. Available at: Http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/022264s006lbl.pdf. Accessed March 8 2012
22. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-Analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011;14:417-28
23. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-Acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
24. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
25. Ward A, Ishak K, Proskorovsky I, et al. Prescriptions for atypical antipsychotic agents and its association with the risks for hospitalisation, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study. Clin Ther 2006;28:11
26. Leucht S, Corves C, Arbter D, et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: A meta-Analysis. Lancet 2009;373:31-41
27. Swedish national inpatient care statistics (hospitalization; average length of stay; schizophrenia diagnosis F20) 2008. Available at: Http://192.137.163.40/epcfs/ParRes.asp. Accessed March 8 2012
28. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-Acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;15:107-118
29. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-44
30. Keks NA, Ingham M, Khan A, et al. Long-Acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9
31. Olanzapine pamoate Summary of Product Characteristics (Lilly) 2010
32. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacology 2011;25:685-97
33. Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-Acting, injectable risperidone: Results from a long-term study. Schizophr Res 2005;77:129-39
34. Schreiner A. Niehaus D. Shuriquie N.A. et al. (2011) Metabolic effects with paliperidone ER versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial, J Clin Psychopharmacology in press
35. Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Spain. ISPOR European Annual European Congress, 20-23 October Dublin, Ireland
36. Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects with paliperidone ER versus oral olanzapine in patients with schizophrenia: A prospective, randomized, controlled trial. J Clin Psychopharmacology 2011, in press 35. Olivares JM, Rodriguez-Morales A, Diels J, et al. 24-month treatment discontinuation rates in patients with schizophrenia treated with Risperidone Long-Acting Injection (RLAI) versus oral antipsychotics: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Spain. ISPOR European Annual European Congress, 20-23 October 2007; Dublin, Ireland 36. Mehnert A, Diels J. Impact of administration interval on treatment retention with long-Acting antipsychotics in schizophrenia. Tenth Workshop on Costs and Assessment in Psychiatry - Mental Health Policy and Economics, 25-27 March 2011; Venice, Italy
37. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: Costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
38. Statistikdatabaser. (2008). Diagnoser i slutenva rd, Socialstyrelsen, Epidemiologiskt centrum. Available at www.socialstyrelsen.se. Accessed March 8 2012
39. Maehlum E, Hensen K. Pharmacoeconomic positioning of sertindole among antipsychotics in the management of schizophrenia in Norway. Value Health 2008;11:A585
40. Johnson & Johnson Pharmaceuticals. Clinical study report (CSR), data on file. PSY-3001N, 2009
41. Tenback De, van Harten PN, Slooff CJ, et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 2009;24:1031-5
42. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005;353:1209-23
43. Ösby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000;5:21-8
44. Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health Qual Life Outcomes 2008;6:105
45. LFNAR. General guidelines for economic evaluations from the Pharmaceutical Benefits Board, 2003
46. Paliperidone palmitate Summary of Product Characteristics (Janssen) 2011
47. World Health Organization Collaborating Centre for Drug Statistics Methodology. (2010). ATC/DDD. Available at http://www.whocc.no/atc-ddd-index/. Accessed March 8 2012
48. TLV available at: Http://www.tlv.se. Accessed March 8 2012
49. BSC. (2009). Using the rate for Health goods for November 2009: Http://www.scb.se/Pages/List-250611.aspx. Accessed March 8 2012
50. Ringborg A, Martinell M, Stalhammar J, et al. Resource use and costs of type 2 diabetes in Sweden-estimates from population-based register data. Int J Clin Pract 2008;62:708-16
51. Drummond MD, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. New York, USA: Oxford University Press, 2005
52. Laux G, Hee BMS, van Hout BA, et al. Costs and effects of long-Acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:49-61
53. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997;17:298-307
54. Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-Acting risperidone in Canada. Pharmacoeconomics 2005;23:62-74
55. Alphs L, Bossie C, Kern Sliwa J, et al. Paliperidone palmitate: Clinical response in subjects with schizophrenia with recent diagnosis vs. longer-time since diagnosis. APA, 16-21 May 2009; San Francisco, USA. Poster NR6-027
56. Olivares JM, Peuskens J, Pecenak J, et al. Clinical and resource-use outcomes of risperidone long-Acting injection in recent and long-term diagnosed schizophrenia patients: Results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
57. Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
58. Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: Healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943-55